Candida albicans
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA273876 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Fungal infections are a serious health problem in the clinic especially in the immunocompromised patient. Disease ranges from widespread superficial vulvovaginal infections to life-threatening systemic candidiasis. Especially for systemic mycoses only a limited arsenal of antimycotica are available, including azoles, polyenes, echinocandines and amphothericin B. Due to emerging resistance to standard therapy and significant side effects for some antimycotica there is a medical need for new antifungals in the clinic and general practice. In order to expand the arsenal of compounds with antifungal activities we screened compound libraries, including combinatorial libraries as well as more than 30 000 pure compounds derived from organic synthesis for antimycotic activity. In total more than 100 000 compounds were screened using an innovative AS (activity-selectivity) assay analyzing both the antifungal activity and the compatability with human cells at the same time. One promising hit, a Benzimidazol-2-yl-alkylamine derivative, was developed in a series of lead compounds showing potent antifungal activity. ((1S)-1-[1-(3-chlorobenzyl)-1H-benzimidazol-2-yl]-2-methylpropyl-amine) (EMC120B12) showed the highest antifungal activity and best compatability with human cells in several cell culture models and against a number of different yeasts and clinical isolates. Transcriptional profiling indicates that the newly discovered compound is a potential inhibitor of the ergosterol-pathway.
2011-07-15 | GSE21622 | GEO
Project description:Gene expression response to the antifungal compound sampangine in C. albicans
| PRJNA108963 | ENA
Project description:Fungal infections are a serious health problem in the clinic especially in the immunocompromised patient. Disease ranges from widespread superficial vulvovaginal infections to life-threatening systemic candidiasis. Especially for systemic mycoses only a limited arsenal of antimycotica are available, including azoles, polyenes, echinocandines and amphothericin B. Due to emerging resistance to standard therapy and significant side effects for some antimycotica there is a medical need for new antifungals in the clinic and general practice. In order to expand the arsenal of compounds with antifungal activities we screened compound libraries, including combinatorial libraries as well as more than 30 000 pure compounds derived from organic synthesis for antimycotic activity. In total more than 100 000 compounds were screened using an innovative AS (activity-selectivity) assay analyzing both the antifungal activity and the compatability with human cells at the same time. One promising hit, a Benzimidazol-2-yl-alkylamine derivative, was developed in a series of lead compounds showing potent antifungal activity. ((1S)-1-[1-(3-chlorobenzyl)-1H-benzimidazol-2-yl]-2-methylpropyl-amine) (EMC120B12) showed the highest antifungal activity and best compatability with human cells in several cell culture models and against a number of different yeasts and clinical isolates. Transcriptional profiling indicates that the newly discovered compound is a potential inhibitor of the ergosterol-pathway. In total, three biological replicates were performed. All experiments were performed as dye swaps. Thus, in total six arrays have been hybridzed. Hybridization experiments included an untreated reference sample and a sample of cells treated with ((1S)-1-[1-(3-chlorobenzyl)-1H-benzimidazol-2-yl]-2-methylpropyl-amine) (EMC120B12). The array included one technical replicate of each probe.
2011-07-14 | E-GEOD-21622 | biostudies-arrayexpress
Project description:An antifungal benzimidazol reveals novel sterols after inhibition of Erg11.
| PRJNA272618 | ENA
Project description:Response of Candida albicans towards a novel antifungal benzimidazole derivative
| PRJNA127111 | ENA
Project description:Candida albicans were treated with a sublethal concentration of the antifungal Jagaricin for either a short time (30 min) or until an OD of 0.5 (indicating log growth) was reached. Controls were grown without any antifungal to determine cellular reactions to the compound.
2019-06-14 | E-MTAB-7718 | biostudies-arrayexpress
Project description:Identification and characterization of potent, broad-spectrum antifungal compounds using a yeast reporter bioassay.
| PRJNA150897 | ENA
Project description:To determine the potential mode of action of the new antifungal compound candidate keanumycin A, the C. albicans wild type SC5314 was exposed to a sublethal dose of the substance. Untreated samples serve as control.
2023-05-31 | E-MTAB-12311 | biostudies-arrayexpress
Project description:Identification and functional characterization of Rca1, a transcription factor involved in both antifungal susceptibility and host response in Candida albicans
| PRJNA162887 | ENA
Project description:Antifungal effect of Sesamol (Ses) on C. albicans SC5314
| PRJNA324697 | ENA